A research institute focused on outsmarting cancer and impacting lives through cancer research.

Oncode Institute

Oncode Institute is an independent institute dedicated to understanding cancer and translating research into practice. Oncode, starting from a deeper understanding of the basics of cancer, works to come up with better treatments and improved diagnostics. 

Our goal: helping more patients survive, improving the quality of life for those afflicted, and ultimately curing cancer.

The complexity of cancer calls for strategic action and collaboration. Instead of new buildings, we are constructing a network, in which experienced, leading scientists and gifted young researchers at partner institutions strive together toward a greater, common goal, supported by KWF Kankerbestrijding and the Dutch Government. Because only by working together we can outsmart cancer. 

Official launch on February 5th, 2018

If you have any questions or suggestions, please feel free to contact us at anytime. 

info@oncode.nl 


We congratulate Oncode Investigators Ruben van Boxtel (Prinses Máxima Centrum voor kinderoncologie) and Jop Kind (Hubrecht Institute, Developmental Biology and Stem Cell Research), who both received an ERC Proof of Concept grant from the European Research Council (ERC)! With this grant of €150.000, the investigators can turn their research into practical applications to benefit cancer patients. 

Ruben van Boxtel will use the funds to further develop his Artificial Intelligence-based assay that predicts safety of antiviral drugs that are often used in children under treatment for cancer and susceptible to severe viral infections. The technology will provide important support to enable modifications for development of safer and less toxic new anti-viral agents.

Jop Kind will use the funds to further develop and commercialize his technology that employs innovative multiplexed epigenetic profiling in blood plasma to improve early cancer detection. For this he will also team up with Oncode Investigator Jan Paul Medema (Amsterdam UMC).

We are proud that Ruben and Jop secured this prestigious valorization grant, and look forward to working with them to bring the project outcomes to the patients!

We congratulate Oncode Investigator Jacco van Rheenen (The Netherlands Cancer Institute), who has been selected as a new member by the renowned life sciences organization EMBO, the European Molecular Biology Organization!
Election as EMBO member is a lifelong honor which recognizes a scientist’s research excellence and outstanding achievements. 

Read the EMBO press release: https://lnkd.in/eapCTcZV

Our valorisation expert Alexander Turkin, PhD organised a break-out session at the “The rapidly evolving field of nuclear medicine” event by Future Affordable Sustainable Therapies. About a quarter of the 100 attendees gathered at the session to talk about the innovation and valorisation challenges in the Netherlands in general, and also specifically in the field of Nuclear Medicine. 
In a lively discussion, the participants raised a number of important points, such as involvement of entrepreneurs and industry in early stages of valorisation as well as extrapolation of Oncode Institute’s centralised valorisation approach to the field of Nuclear Medicine.
We thank Martinus Blauwhoff for co-organising, and everyone for their active contribution at the session, and look forward to continuing this important dialogue with all stakeholders!

With a great second day coming to an end, the Oncode Institute Annual Meeting 2024 is now in the books!

We’d like to thank the Scientific Committee - Oncode Investigators Titia Sixma and Daniela Thommen (both at The Netherlands Cancer Institute); Laura Heitman (Leiden Academic Centre for Drug Research) and Jop Kind (Hubrecht Institute, Developmental Biology and Stem Cell Research) - and all the speakers and poster presenters for their great contributions.

A special thank you also to Stein Aerts (VIB & KU Leuven) and to John Haanen (The Netherlands Cancer Institute).

Keep an eye on our website - a full event report will follow soon. #AM2024
Photos: Rob ter Bekke.

And here we go! We're halfway through the first day of the Oncode Institute Annual Meeting 2024! We have a full house for these two days, and a program packed with science, networking, poster presentations and special sessions. #AM2024

Podcast alert! Check out the latest episode of Leaders in Life Sciences featuring our Scientific Director and Head of the Institute, Jan Paul Medema in conversation with host Henk Jan Out - for insight into the layers and challenges of finding solutions for cancer, and an in depth understanding of what Oncode Institute is all about.

For more: https://lnkd.in/gbPxgpNz

Metric
Company Name	Oncode Institute
Symbol
MSH ID	NL:ONCODEINSTITUTE
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Research
Country	NL
Stage
Employee Count	75
Website	oncodeinstitute.nl
LinkedIn	oncode-institute
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ONCO

NL:ONCODEINSTITUTE

Oncode Institute

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue